Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed Patients

Richard J. Whitley, Seng Jaw Soong, G. Galasso, M. Myers, S. Straus, R. Whitley, C. Alford, N. Barton, C. G. Cobbs, S. Soong, P. Kartus, J. Overall, F. Hayden, J. Gwaltney, M. Hilty, R. Glaser, R. Turner, C. Linnemann, C. Liu, D. HinthornC. T. Cho, G. R. Hodges, J. Luby, K. Murphy, S. Schwartzman, A. Nahmias, J. Connor, D. Richman, M. Oxman, S. Spector, Y. Bryson, M. Ho, G. Pazin, J. Dowling, M. Hirsch, A. Karchmer, J. Tilles, R. Betts, R. G. Douglas, A. Chow, R. Haynes, Raphael Dolin, R. C. Reichman, R. Buchanan, S. Thornton, Calvin Linnemann, Charles A. Alford

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

We conducted a double-blind, placebo-controlled trial to assess the value of vidarabine therapy for the prevention of complications from herpes zoster in immunocompromised patients. Of 121 patients with localized herpes zoster of 72 hours' duration or less, 63 received vidarabine and 58 received the placebo. Populations were matched for pertinent characteristics. Therapy accelerated cutaneous healing and decreased the rates of cutaneous dissemination (from 24 per cent [14 patients] to 8 per cent [5 patients]) (P = 0.014); and of zoster-related visceral complications (from 19 per cent [11 patients] to 5 per cent [3 patients]) (P = 0.015). Therapy also decreased the total duration of post-herpetic neuralgia (P = 0.047). Patients with lymphoproliferative cancers and those 38 years of age or older were at greatest risk for complications and benefited most from therapy. There was no serious drug toxicity. We conclude that vidarabine therapy, when started within the first three days, is valuable for the reduction of complications related to herpes zoster. (N Engl J Med. 1982; 307:971–5.) Herpes zoster, a common infection in immunocompromised patients, can be life-threatening if the viscera become involved.1 2 3 4 As a consequence, herpes-zoster infections have become targets for experimental antiviral trials. In 1976, we reported the results of a blind, controlled, crossover study of vidarabine therapy for herpes-zoster infections in the immunocompromised host, which demonstrated accelerated cutaneous healing,5 especially in patients who were 38 years of age or less, had lymphoproliferative cancers, and received therapy within six days of the onset of disease.6 Because of the crossover design of the study, the value of vidarabine for the prevention of complications (such as post-herpetic.

Original languageEnglish (US)
Pages (from-to)971-975
Number of pages5
JournalNew England Journal of Medicine
Volume307
Issue number16
DOIs
StatePublished - Oct 14 1982

Fingerprint

Vidarabine
Herpes Zoster
Secondary Prevention
Immunocompromised Host
Cross-Over Studies
Skin
Therapeutics
Infection
Placebos
Viscera
Neuralgia
Drug-Related Side Effects and Adverse Reactions
Antiviral Agents
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Whitley, R. J., Soong, S. J., Galasso, G., Myers, M., Straus, S., Whitley, R., ... Alford, C. A. (1982). Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed Patients. New England Journal of Medicine, 307(16), 971-975. https://doi.org/10.1056/NEJM198210143071602

Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed Patients. / Whitley, Richard J.; Soong, Seng Jaw; Galasso, G.; Myers, M.; Straus, S.; Whitley, R.; Alford, C.; Barton, N.; Cobbs, C. G.; Soong, S.; Kartus, P.; Overall, J.; Hayden, F.; Gwaltney, J.; Hilty, M.; Glaser, R.; Turner, R.; Linnemann, C.; Liu, C.; Hinthorn, D.; Cho, C. T.; Hodges, G. R.; Luby, J.; Murphy, K.; Schwartzman, S.; Nahmias, A.; Connor, J.; Richman, D.; Oxman, M.; Spector, S.; Bryson, Y.; Ho, M.; Pazin, G.; Dowling, J.; Hirsch, M.; Karchmer, A.; Tilles, J.; Betts, R.; Douglas, R. G.; Chow, A.; Haynes, R.; Dolin, Raphael; Reichman, R. C.; Buchanan, R.; Thornton, S.; Linnemann, Calvin; Alford, Charles A.

In: New England Journal of Medicine, Vol. 307, No. 16, 14.10.1982, p. 971-975.

Research output: Contribution to journalArticle

Whitley, RJ, Soong, SJ, Galasso, G, Myers, M, Straus, S, Whitley, R, Alford, C, Barton, N, Cobbs, CG, Soong, S, Kartus, P, Overall, J, Hayden, F, Gwaltney, J, Hilty, M, Glaser, R, Turner, R, Linnemann, C, Liu, C, Hinthorn, D, Cho, CT, Hodges, GR, Luby, J, Murphy, K, Schwartzman, S, Nahmias, A, Connor, J, Richman, D, Oxman, M, Spector, S, Bryson, Y, Ho, M, Pazin, G, Dowling, J, Hirsch, M, Karchmer, A, Tilles, J, Betts, R, Douglas, RG, Chow, A, Haynes, R, Dolin, R, Reichman, RC, Buchanan, R, Thornton, S, Linnemann, C & Alford, CA 1982, 'Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed Patients', New England Journal of Medicine, vol. 307, no. 16, pp. 971-975. https://doi.org/10.1056/NEJM198210143071602
Whitley, Richard J. ; Soong, Seng Jaw ; Galasso, G. ; Myers, M. ; Straus, S. ; Whitley, R. ; Alford, C. ; Barton, N. ; Cobbs, C. G. ; Soong, S. ; Kartus, P. ; Overall, J. ; Hayden, F. ; Gwaltney, J. ; Hilty, M. ; Glaser, R. ; Turner, R. ; Linnemann, C. ; Liu, C. ; Hinthorn, D. ; Cho, C. T. ; Hodges, G. R. ; Luby, J. ; Murphy, K. ; Schwartzman, S. ; Nahmias, A. ; Connor, J. ; Richman, D. ; Oxman, M. ; Spector, S. ; Bryson, Y. ; Ho, M. ; Pazin, G. ; Dowling, J. ; Hirsch, M. ; Karchmer, A. ; Tilles, J. ; Betts, R. ; Douglas, R. G. ; Chow, A. ; Haynes, R. ; Dolin, Raphael ; Reichman, R. C. ; Buchanan, R. ; Thornton, S. ; Linnemann, Calvin ; Alford, Charles A. / Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed Patients. In: New England Journal of Medicine. 1982 ; Vol. 307, No. 16. pp. 971-975.
@article{d6a258a1989e435c8ab8a58bb846d543,
title = "Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed Patients",
abstract = "We conducted a double-blind, placebo-controlled trial to assess the value of vidarabine therapy for the prevention of complications from herpes zoster in immunocompromised patients. Of 121 patients with localized herpes zoster of 72 hours' duration or less, 63 received vidarabine and 58 received the placebo. Populations were matched for pertinent characteristics. Therapy accelerated cutaneous healing and decreased the rates of cutaneous dissemination (from 24 per cent [14 patients] to 8 per cent [5 patients]) (P = 0.014); and of zoster-related visceral complications (from 19 per cent [11 patients] to 5 per cent [3 patients]) (P = 0.015). Therapy also decreased the total duration of post-herpetic neuralgia (P = 0.047). Patients with lymphoproliferative cancers and those 38 years of age or older were at greatest risk for complications and benefited most from therapy. There was no serious drug toxicity. We conclude that vidarabine therapy, when started within the first three days, is valuable for the reduction of complications related to herpes zoster. (N Engl J Med. 1982; 307:971–5.) Herpes zoster, a common infection in immunocompromised patients, can be life-threatening if the viscera become involved.1 2 3 4 As a consequence, herpes-zoster infections have become targets for experimental antiviral trials. In 1976, we reported the results of a blind, controlled, crossover study of vidarabine therapy for herpes-zoster infections in the immunocompromised host, which demonstrated accelerated cutaneous healing,5 especially in patients who were 38 years of age or less, had lymphoproliferative cancers, and received therapy within six days of the onset of disease.6 Because of the crossover design of the study, the value of vidarabine for the prevention of complications (such as post-herpetic.",
author = "Whitley, {Richard J.} and Soong, {Seng Jaw} and G. Galasso and M. Myers and S. Straus and R. Whitley and C. Alford and N. Barton and Cobbs, {C. G.} and S. Soong and P. Kartus and J. Overall and F. Hayden and J. Gwaltney and M. Hilty and R. Glaser and R. Turner and C. Linnemann and C. Liu and D. Hinthorn and Cho, {C. T.} and Hodges, {G. R.} and J. Luby and K. Murphy and S. Schwartzman and A. Nahmias and J. Connor and D. Richman and M. Oxman and S. Spector and Y. Bryson and M. Ho and G. Pazin and J. Dowling and M. Hirsch and A. Karchmer and J. Tilles and R. Betts and Douglas, {R. G.} and A. Chow and R. Haynes and Raphael Dolin and Reichman, {R. C.} and R. Buchanan and S. Thornton and Calvin Linnemann and Alford, {Charles A.}",
year = "1982",
month = "10",
day = "14",
doi = "10.1056/NEJM198210143071602",
language = "English (US)",
volume = "307",
pages = "971--975",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed Patients

AU - Whitley, Richard J.

AU - Soong, Seng Jaw

AU - Galasso, G.

AU - Myers, M.

AU - Straus, S.

AU - Whitley, R.

AU - Alford, C.

AU - Barton, N.

AU - Cobbs, C. G.

AU - Soong, S.

AU - Kartus, P.

AU - Overall, J.

AU - Hayden, F.

AU - Gwaltney, J.

AU - Hilty, M.

AU - Glaser, R.

AU - Turner, R.

AU - Linnemann, C.

AU - Liu, C.

AU - Hinthorn, D.

AU - Cho, C. T.

AU - Hodges, G. R.

AU - Luby, J.

AU - Murphy, K.

AU - Schwartzman, S.

AU - Nahmias, A.

AU - Connor, J.

AU - Richman, D.

AU - Oxman, M.

AU - Spector, S.

AU - Bryson, Y.

AU - Ho, M.

AU - Pazin, G.

AU - Dowling, J.

AU - Hirsch, M.

AU - Karchmer, A.

AU - Tilles, J.

AU - Betts, R.

AU - Douglas, R. G.

AU - Chow, A.

AU - Haynes, R.

AU - Dolin, Raphael

AU - Reichman, R. C.

AU - Buchanan, R.

AU - Thornton, S.

AU - Linnemann, Calvin

AU - Alford, Charles A.

PY - 1982/10/14

Y1 - 1982/10/14

N2 - We conducted a double-blind, placebo-controlled trial to assess the value of vidarabine therapy for the prevention of complications from herpes zoster in immunocompromised patients. Of 121 patients with localized herpes zoster of 72 hours' duration or less, 63 received vidarabine and 58 received the placebo. Populations were matched for pertinent characteristics. Therapy accelerated cutaneous healing and decreased the rates of cutaneous dissemination (from 24 per cent [14 patients] to 8 per cent [5 patients]) (P = 0.014); and of zoster-related visceral complications (from 19 per cent [11 patients] to 5 per cent [3 patients]) (P = 0.015). Therapy also decreased the total duration of post-herpetic neuralgia (P = 0.047). Patients with lymphoproliferative cancers and those 38 years of age or older were at greatest risk for complications and benefited most from therapy. There was no serious drug toxicity. We conclude that vidarabine therapy, when started within the first three days, is valuable for the reduction of complications related to herpes zoster. (N Engl J Med. 1982; 307:971–5.) Herpes zoster, a common infection in immunocompromised patients, can be life-threatening if the viscera become involved.1 2 3 4 As a consequence, herpes-zoster infections have become targets for experimental antiviral trials. In 1976, we reported the results of a blind, controlled, crossover study of vidarabine therapy for herpes-zoster infections in the immunocompromised host, which demonstrated accelerated cutaneous healing,5 especially in patients who were 38 years of age or less, had lymphoproliferative cancers, and received therapy within six days of the onset of disease.6 Because of the crossover design of the study, the value of vidarabine for the prevention of complications (such as post-herpetic.

AB - We conducted a double-blind, placebo-controlled trial to assess the value of vidarabine therapy for the prevention of complications from herpes zoster in immunocompromised patients. Of 121 patients with localized herpes zoster of 72 hours' duration or less, 63 received vidarabine and 58 received the placebo. Populations were matched for pertinent characteristics. Therapy accelerated cutaneous healing and decreased the rates of cutaneous dissemination (from 24 per cent [14 patients] to 8 per cent [5 patients]) (P = 0.014); and of zoster-related visceral complications (from 19 per cent [11 patients] to 5 per cent [3 patients]) (P = 0.015). Therapy also decreased the total duration of post-herpetic neuralgia (P = 0.047). Patients with lymphoproliferative cancers and those 38 years of age or older were at greatest risk for complications and benefited most from therapy. There was no serious drug toxicity. We conclude that vidarabine therapy, when started within the first three days, is valuable for the reduction of complications related to herpes zoster. (N Engl J Med. 1982; 307:971–5.) Herpes zoster, a common infection in immunocompromised patients, can be life-threatening if the viscera become involved.1 2 3 4 As a consequence, herpes-zoster infections have become targets for experimental antiviral trials. In 1976, we reported the results of a blind, controlled, crossover study of vidarabine therapy for herpes-zoster infections in the immunocompromised host, which demonstrated accelerated cutaneous healing,5 especially in patients who were 38 years of age or less, had lymphoproliferative cancers, and received therapy within six days of the onset of disease.6 Because of the crossover design of the study, the value of vidarabine for the prevention of complications (such as post-herpetic.

UR - http://www.scopus.com/inward/record.url?scp=0019986490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019986490&partnerID=8YFLogxK

U2 - 10.1056/NEJM198210143071602

DO - 10.1056/NEJM198210143071602

M3 - Article

C2 - 7110300

AN - SCOPUS:0019986490

VL - 307

SP - 971

EP - 975

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -